What does US7803839B2 cover, and how is it tied to Exelixis or cobimetinib?
I can’t determine from your prompt what US7803839B2 is about or whether it is specifically associated with Exelixis’ cobimetinib without the patent’s key text (for example, the title/abstract or a link to the Google Patents page). “US7803839B2” is a grant number, but the meaning depends entirely on the invention described in that specific document.
If you paste the Google Patents link (or the patent title/abstract), I can map it to:
- whether it mentions cobimetinib (GDC-0973) or related chemical entities,
- whether the assignee is Exelixis or a different entity,
- the claimed subject matter (composition, synthesis, methods of treatment, dosing, polymorphs, etc.),
- and how that might relate to cobimetinib commercialization or litigation.
Where to find US7803839B2 on Google Patents (fast)
On Google Patents, search for the exact number:
- “US7803839B2”
Then check these fields on the page:
- Title and Abstract (tells you what the invention is)
- Assignee / Applicant (tells you who owns it)
- Inventors (sometimes reveals who developed it)
- Claims (tells you what is protected)
- Patent citations / family members (helps connect to later improvements)
How can you tell if this patent is “about cobimetinib”?
Even if a patent is in the same company family, it may not actually claim cobimetinib. To confirm, look for any of the following on the Google Patents page (especially in claims):
- explicit reference to cobimetinib or GDC-0973 by name/code
- chemical structure identifiers or examples matching cobimetinib’s chemical class
- “a MEK inhibitor” claims broad enough to include cobimetinib (but not necessarily limited to it)
- method-of-treatment claims for tumors that cobimetinib treats, where cobimetinib is part of the defined disclosure
Who is likely the assignee for US7803839B2—and why it matters
The assignee on the Google Patents page is the key clue for whether Exelixis is involved. If the assignee is different (for example, a developer of MAP2K/MEK inhibitors, a university, or another pharma entity), that doesn’t rule out Exelixis involvement, but it may mean Exelixis is only a licensee or later partner.
What’s the typical next question after seeing a “MEK inhibitor” patent?
People usually want to know one of these:
- Does the patent cover the drug molecule itself, or manufacturing/processing, or therapeutic use?
- Is it still in force (or when does it expire, considering filing/grant dates)?
- Are there continuation applications or related family members with broader claims?
- Is the patent part of any infringement dispute involving cobimetinib?
If you share the Google Patents URL for US7803839B2, I can answer those precisely for that document (and, if you want, list related family members and what each one covers).
Share the missing detail
Send either:
1) the Google Patents link to US7803839B2, or
2) the patent title + assignee + abstract text
…and I’ll connect it directly to Exelixis and cobimetinib using the document’s own claims and identifiers.